GB0914767D0 - Compound - Google Patents

Compound

Info

Publication number
GB0914767D0
GB0914767D0 GBGB0914767.9A GB0914767A GB0914767D0 GB 0914767 D0 GB0914767 D0 GB 0914767D0 GB 0914767 A GB0914767 A GB 0914767A GB 0914767 D0 GB0914767 D0 GB 0914767D0
Authority
GB
United Kingdom
Prior art keywords
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0914767.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sterix Ltd
Original Assignee
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterix Ltd filed Critical Sterix Ltd
Priority to GBGB0914767.9A priority Critical patent/GB0914767D0/en
Publication of GB0914767D0 publication Critical patent/GB0914767D0/en
Priority to PCT/GB2010/051391 priority patent/WO2011023989A1/en
Priority to JP2012526125A priority patent/JP5828839B2/ja
Priority to EP10750154.6A priority patent/EP2470512B1/en
Priority to CN201080037827.XA priority patent/CN102596919B/zh
Priority to US13/392,206 priority patent/US8846737B2/en
Priority to RU2012111119/04A priority patent/RU2572244C2/ru
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0914767.9A 2009-08-24 2009-08-24 Compound Ceased GB0914767D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0914767.9A GB0914767D0 (en) 2009-08-24 2009-08-24 Compound
PCT/GB2010/051391 WO2011023989A1 (en) 2009-08-24 2010-08-23 Aromatase inhibitor
JP2012526125A JP5828839B2 (ja) 2009-08-24 2010-08-23 アロマターゼ阻害剤
EP10750154.6A EP2470512B1 (en) 2009-08-24 2010-08-23 Aromatase inhibitor
CN201080037827.XA CN102596919B (zh) 2009-08-24 2010-08-23 芳香酶抑制剂
US13/392,206 US8846737B2 (en) 2009-08-24 2010-08-23 Compound
RU2012111119/04A RU2572244C2 (ru) 2009-08-24 2010-08-23 Ингибиторы ароматазы

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0914767.9A GB0914767D0 (en) 2009-08-24 2009-08-24 Compound

Publications (1)

Publication Number Publication Date
GB0914767D0 true GB0914767D0 (en) 2009-09-30

Family

ID=41171838

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0914767.9A Ceased GB0914767D0 (en) 2009-08-24 2009-08-24 Compound

Country Status (7)

Country Link
US (1) US8846737B2 (https=)
EP (1) EP2470512B1 (https=)
JP (1) JP5828839B2 (https=)
CN (1) CN102596919B (https=)
GB (1) GB0914767D0 (https=)
RU (1) RU2572244C2 (https=)
WO (1) WO2011023989A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100609A1 (en) * 2013-12-31 2015-07-09 Beaufour Ipsen Tianjin Pharmaceutical Co., Ltd New substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase
DE102017116299A1 (de) 2017-07-19 2019-01-24 Huf Hülsbeck & Fürst Gmbh & Co. Kg Verfahren zum Zuordnen einer Reifendrucküberwachungseinheit zu einer Radposition eines Fahrzeugs
MX2020003242A (es) 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
LT3728207T (lt) 2017-12-21 2023-05-25 Ribon Therapeutics Inc. Chinazolinonai kaip parp14 inhibitoriai
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
PL239999B1 (pl) * 2018-06-18 2022-02-07 Politechnika Gdanska A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu
CN113387894B (zh) * 2021-06-22 2023-02-24 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 1-n-苯乙腈基氨基-三氮唑和嘧啶衍生物及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB9003939D0 (en) 1990-02-21 1990-04-18 Imperial College Sulphatase inhibitors
TW210334B (https=) * 1990-12-12 1993-08-01 Ciba Geigy Ag
CH683151A5 (de) 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
GB9118478D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
TW225526B (https=) 1991-09-02 1994-06-21 Yamanouchi Pharma Co Ltd
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
GB9422777D0 (en) 1994-11-11 1995-01-04 Imperial College Assay
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DE69729007T2 (de) 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
ATE424410T1 (de) 1996-08-30 2009-03-15 Human Genome Sciences Inc Interleukin-19.
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
KR100517452B1 (ko) 1996-09-25 2007-03-15 히사미쓰 메디카루 가부시키가이샤 치환 비닐피리딘 유도체 및 이를 함유하는 의약
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6585954B1 (en) 1998-03-26 2003-07-01 Kyowa Hakko Kogyo Co., Ltd. Method for searching steroid sulfatase inhibitors
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
CA2464770C (en) 2001-11-21 2011-08-16 Sterix Limited Compound
EP1431292A1 (en) * 2002-12-16 2004-06-23 Laboratoire Theramex 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors
EP1544195A1 (en) 2003-12-15 2005-06-22 Laboratoire Theramex 1-N-phenyl-amino- 1H-imidazole derivatives and pharmaceutical compositions containing them
BRPI0417407A (pt) * 2003-12-15 2007-04-03 Theramex derivados de 1-n-fenil-amino-1h-imidazol e composições farmacêuticas contendo estes
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
EP2037884A2 (en) * 2006-06-22 2009-03-25 Novartis AG Sustained release formulations of aromatase inhibitors

Also Published As

Publication number Publication date
EP2470512A1 (en) 2012-07-04
JP2013502451A (ja) 2013-01-24
JP5828839B2 (ja) 2015-12-09
RU2572244C2 (ru) 2016-01-10
EP2470512B1 (en) 2018-05-02
WO2011023989A1 (en) 2011-03-03
US20120238550A1 (en) 2012-09-20
US8846737B2 (en) 2014-09-30
CN102596919B (zh) 2015-11-25
RU2012111119A (ru) 2013-10-10
CN102596919A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
IL213992A (en) Pro-neurogenic compounds
IL215147A0 (en) Compounds
EP2423182A4 (en) DIACYLETHYLENEDIAMINE COMPOUND
GB0907425D0 (en) Compounds
GB0903759D0 (en) Compound
EP2393493A4 (en) LINKS
GB0907515D0 (en) Compounds
GB0919194D0 (en) Compounds
GB0914767D0 (en) Compound
GB0922302D0 (en) Compounds
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
GB0909213D0 (en) Compound
EP2487178A4 (en) PYRAZOLOTHIAZOLVERBINDUNG
GB0909672D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0914883D0 (en) Compound
GB0911000D0 (en) Compounds
EP2443115A4 (en) COMPOUNDS
GB0901976D0 (en) Compound
GB0922714D0 (en) Compound
GB0910692D0 (en) Compound
GB0917460D0 (en) Compound
GB0922003D0 (en) Compound
GB0906821D0 (en) Compound

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)